Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company.

Rhea-AI Summary

Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company. According to Entera Bio, the financing is expected to extend its cash runway into 2030 and fully support Phase 3 registrational studies of EB613, an oral PTH (1-34) tablet in development for osteoporosis.

According to data compiled by Arx Capital Markets, this is the largest publicly disclosed Israeli biotech PIPE on record and the ninth largest Israeli PIPE overall. The Greenberg Traurig deal team was led from Miami with support from the firm’s Tel Aviv office.

Positive

• $275 million oversubscribed PIPE financing completed
• Funding expected to extend cash runway into 2030
• Financing expected to fully support Phase 3 EB613 registrational studies
• Largest publicly disclosed Israeli biotech PIPE on record

Negative

• None.

Argus Jul 29 session 16 alerts

-7.98% close to close 0.3x rel. volume Open Argus

Details

Market move: ENTX -7.98% in the Jul 29 session. 275M PIPE financing

+3.8% Peak Tracked

-13.8% Trough Tracked

$211.00M Market Cap

On Jul 29, the day this news came out, ENTX closed 7.98% below the previous close. Argus tracked a peak move of +3.8% during that session. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner recorded 16 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 29 session.

Key Figures

Private placement: $275 million Cash runway: 2030 Trial phase: Phase 3 +1 more

Private placement

$275 million

Oversubscribed financing

Cash runway

2030

Expected runway extension

Trial phase

Phase 3

Registrational studies for EB613 in osteoporosis

Israeli PIPE ranking

9th largest

Across all Israeli industries

Historical Context

5 past events · Latest: Jun 22

5 events

1. Jun 22

   FDA protocol feedback

   24h Move

   +22.3%

   FDA accepted a single 750-patient Phase 3 trial protocol for EB613.

2. Jun 16

   Preclinical data

   24h Move

   -2.5%

   Preclinical EB612 and EB618 data supported advancement toward clinical development.

3. Jun 15

   Phase 1 data

   24h Move

   -1.6%

   Comparative Phase 1 EB613 data supported selection of the single-tablet candidate.

4. May 28

   Conference presentation acceptance

   24h Move

   +2.5%

   Multiple oral peptide pipeline abstracts were accepted for ENDO 2026 presentations.

5. May 08

   Quarterly results

   24h Move

   -10.0%

   Q1 results and program updates included funding and Phase 3 preparation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pipe, pth (1-34), registrational studies, private investment in public equity

4 terms

pipe financial

"its oversubscribed $275 million private placement financing"

A PIPE (private investment in public equity) is a deal in which institutional or accredited investors buy shares or convertible securities directly from a publicly traded company, usually at a discount to the market price. Companies use PIPEs to raise money faster than through a traditional public offering; for existing shareholders they matter because the newly issued shares add to the share count and can dilute ownership.

pth (1-34) medical

"the first oral PTH (1-34) peptide tablet"

pth (1-34) is a lab-made fragment of the human parathyroid hormone that acts like a short, active version of the natural hormone to stimulate bone growth and increase calcium levels. For investors, it matters because drugs based on this molecule are marketed as treatments for severe osteoporosis and related bone disorders, so clinical trial results, regulatory decisions, manufacturing capacity, and patent status can strongly affect a company’s revenue prospects and stock value.

registrational studies regulatory

"fully support Phase 3 registrational studies for EB613"

Clinical trials run specifically to provide the evidence regulators require for approval of a new drug, device, or treatment. They are the final, rigorous tests—like a product’s “final exam” or blueprint review—that determine whether a therapy can legally be marketed, so their outcomes directly affect a company’s ability to generate revenue, timelines to market and overall investment risk.

private investment in public equity financial

"private investment in public equity (PIPE) on record"

Private investment in public equity occurs when investors buy shares directly from a company that is publicly traded, often at an early stage or at a discount, instead of purchasing them on the open market. This allows investors to acquire a stake more quickly and with potentially better terms, which can influence the company's future growth and stability—making it an important option for those seeking to support or benefit from a company's development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing.

The financing is expected to extend Entera Bio's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH (1-34) peptide tablet in development for the treatment of osteoporosis, according to the company's press release.

This financing is the largest publicly disclosed Israeli biotech private investment in public equity (PIPE) on record and the ninth largest publicly disclosed Israeli PIPE transaction across all industries, according to data compiled by Arx Capital Markets, Entera Bio's investor relations firm.

The Greenberg Traurig team representing Entera Bio in this transaction was led by MiamiCorporate Practice Co-Chair Drew M. Altman and Miami Corporate Shareholder Sami B. Ghneim, with assistance from Miami Corporate Associate Angel A. Marcial and Tel-Aviv office Managing Shareholder Joey T. Shabot.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenberg-traurig-advises-entera-bio-in-record-275m-israeli-biotech-pipe-302838075.html

SOURCE Greenberg Traurig, LLP

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Entera Bio (NASDAQ: ENTX) announce about its new $275 million PIPE financing?

Entera Bio announced an oversubscribed $275 million PIPE financing. According to Entera Bio, the proceeds are expected to extend its cash runway into 2030 and fully fund Phase 3 registrational studies of EB613, its oral PTH (1-34) osteoporosis candidate.

How will the $275 million PIPE impact Entera Bio’s cash runway and development plans for EB613 (ENTX)?

According to Entera Bio, the $275 million PIPE is expected to extend its cash runway into 2030. The company also expects the funding to fully support Phase 3 registrational studies of EB613, its oral osteoporosis therapy candidate, improving visibility on near- to mid-term development costs.

Why is Entera Bio’s $275 million PIPE considered a record transaction for Israeli biotech?

According to data cited by Entera Bio, the $275 million financing is the largest publicly disclosed Israeli biotech PIPE on record. It is also described as the ninth largest publicly disclosed Israeli PIPE transaction across all industries, highlighting its scale in the local capital market.

What is EB613 in Entera Bio’s (ENTX) pipeline and how is the PIPE financing related?

EB613 is described by Entera Bio as the first oral PTH (1-34) peptide tablet in development for osteoporosis. According to Entera Bio, the $275 million PIPE is expected to fully support Phase 3 registrational studies of EB613, covering key late-stage clinical development needs.

Who advised Entera Bio (ENTX) on its $275 million PIPE financing and what was Greenberg Traurig’s role?

Greenberg Traurig advised Entera Bio on the oversubscribed $275 million PIPE transaction. The firm reports the deal team was led by its Miami Corporate Practice Co-Chair and Corporate Shareholder, with additional support from a Miami associate and the Tel Aviv office’s Managing Shareholder.

How significant is the $275 million PIPE for Entera Bio’s Phase 3 plans in osteoporosis?

According to Entera Bio, the $275 million financing is expected to fully fund Phase 3 registrational studies of EB613 for osteoporosis. This suggests the company anticipates having sufficient capital for pivotal trials, assuming plans and cost expectations remain consistent with current projections.